tiprankstipranks
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS

Apellis Pharmaceuticals (APLS) Stock Price & Analysis

754 Followers

APLS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$19.83 - $73.80
Previous Close$39.53
Volume1.67M
Average Volume (3M)1.50M
Market Cap
$4.80B
Enterprise Value$4.58B
Total Cash (Recent Filing)$325.90M
Total Debt (Recent Filing)$109.14M
Price to Earnings (P/E)
Beta0.63
Aug 05, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding121,365,555
10 Day Avg. Volume1,122,999
30 Day Avg. Volume1,501,362
Standard Deviation0.22
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)17.33
Price to Sales (P/S)31.57
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.83
Enterprise Value/Gross Profit13.55
Enterprise Value/Ebitda-11.87
Forecast
Price Target Upside83.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say
EarningsStrong Syfovre sales in 1Q24, with revenues of $137.5M, topping consensus of $129M.
Growth And DemandThe company continues to see double-digit account growth per week since Syfovre's launch, underscoring meaningful demand.
Market ShareAPLS claimed 85% market share for Syfovre, based on the number of GA patients treated.
Bears Say
Competitive PressureIzervay's new J-code is negatively impacting Syfovre's usage, with expectations of decreased usage starting in the second quarter.
Market PerformanceAPLS shares are down 30% year-to-date, primarily due to competition from Izervay and other negative market factors.
Regulatory ApprovalThe European Medicines Agency issued a negative opinion on the potential approval for pegcetacoplan, casting doubt on its future in the European market.
---

Financials

Annual

Ownership Overview

14.93%37.33%14.08%33.65%
14.93% Insiders
14.08% Other Institutional Investors
33.65% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

APLS FAQ

What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $19.83 and its highest was $73.80 in the past 12 months.
    What is Apellis Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
    Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 05, 2024 which is in 21 days.
      How were Apellis Pharmaceuticals Inc’s earnings last quarter?
      Apellis Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.063.
        Is Apellis Pharmaceuticals Inc overvalued?
        According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Apellis Pharmaceuticals Inc pay dividends?
          Apellis Pharmaceuticals Inc does not currently pay dividends.
          What is Apellis Pharmaceuticals Inc’s EPS estimate?
          Apellis Pharmaceuticals Inc’s EPS estimate is -$0.28.
            How many shares outstanding does Apellis Pharmaceuticals Inc have?
            Apellis Pharmaceuticals Inc has 121,365,555 shares outstanding.
              What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
              Apellis Pharmaceuticals Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -10.059%.
                Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
                Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Iron Triangle Partners LP. It holds Apellis Pharmaceuticals Inc’s shares valued at 32M.
                  ---

                  Company Description

                  Apellis Pharmaceuticals Inc

                  Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
                  ---

                  APLS Company Deck

                  ---

                  APLS Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  APLS Stock 12 Month Forecast

                  Average Price Target

                  $72.58
                  ▲(83.61% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","96":"$96","41.25":"$41.3","59.5":"$59.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$72.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.25,59.5,77.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.24,40.760000000000005,45.28,49.8,54.32,58.84,63.36,67.88,72.4,76.91999999999999,81.44,85.96000000000001,90.47999999999999,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.24,39.035384615384615,41.830769230769235,44.62615384615385,47.42153846153846,50.21692307692308,53.012307692307694,55.80769230769231,58.60307692307693,61.39846153846154,64.19384615384615,66.98923076923077,69.78461538461539,{"y":72.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.24,36.99076923076923,37.74153846153846,38.49230769230769,39.24307692307693,39.99384615384616,40.744615384615386,41.495384615384616,42.246153846153845,42.996923076923075,43.747692307692304,44.49846153846154,45.24923076923077,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.5,"date":1689292800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.53,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.03,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.83,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.58,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.61,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.56,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.91,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.46,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.37,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.24,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Curis
                  Genfit SA
                  RegenXBio
                  G1 Therapeutics

                  Best Analysts Covering APLS

                  1 Year
                  Justin KimOppenheimer
                  1 Year Success Rate
                  17/30 ratings generated profit
                  57%
                  1 Year Average Return
                  +14.45%
                  reiterated a buy rating 14 days ago
                  Copying Justin Kim's trades and holding each position for 1 Year would result in 56.67% of your transactions generating a profit, with an average return of +14.45% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis